{"id":27528,"date":"2026-01-19T11:42:26","date_gmt":"2026-01-19T10:42:26","guid":{"rendered":"https:\/\/accelsiors.com\/?page_id=27528"},"modified":"2026-03-17T12:10:24","modified_gmt":"2026-03-17T12:10:24","slug":"acceshield","status":"publish","type":"page","link":"https:\/\/staging-new-site.accelsiors.com\/?page_id=27528","title":{"rendered":"AcceShield\u2122"},"content":{"rendered":"\n
\n

AI Compliance Shield for Clinical Trials<\/h2>\n<\/div>\n\n\n\n
\n

Protect your trials from invisible AI risks with Accelsiors’ ACCESHIELD\u2122. A productized service ensuring EU AI Act compliance, data security, and multi-region alignment for emerging biotechs.<\/p>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Welcome from Dr. Istvan Peter Horvath, Chief Legal & Risk Officer at Accelsiors<\/h2>\n\n\n\n

\u201cI\u2019m proud to introduce ACCESHILD\u2122\u2014our shield against AI risks, grounded in European expertise and designed to protect emerging biotechs like yours. As Accelsiors\u2019 Chief Legal & Risk Officer, I\u2019ve witnessed how \u2018invisible AI\u2019 threats, such as algorithmic drift or silent updates, can jeopardize clinical trials, especially in EU-inclusive studies. That\u2019s why ACCESHILD\u2122 offers a turnkey, execution-focused solution through three phases: Audit for mapping gaps, Remediation for fixing high-risk issues, and Governance for ongoing monitoring and controls. Leveraging our Switzerland-based insights and EU AI Act Readiness Playbook, it ensures defensible data under regulations like the AI Act, GCP, GDPR, and MDR\/IVDR, while bridging to FDA \u2018Context of Use\u2019 for global alignment.<\/p>\n\n\n\n

Beyond AI, we\u2019re committed to NIS 2\/ISO 27001-compliant data security, safeguarding healthcare infrastructure through robust risk management, incident reporting, and supply chain protections. Our audits definitively include NIS 2 compliance assessments, ensuring your trials are resilient against cyber threats and fully prepared for critical sector requirements.<\/p>\n\n\n\n

We go beyond consulting by operationalizing compliance into your workflows, reducing risks by up to 50% and turning regulatory challenges into a competitive advantage, without you needing to build an internal AI or security team. Let\u2019s secure your trials and accelerate your success together.\u201d<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

ACCESHIELD\u2122: Your Turnkey Defense Against AI Risks in Clinical Trials<\/h2>\n<\/div>\n\n\n\n
\n

If you\u2019re an emerging US biotech navigating EU-inclusive studies, our specialized service line shields against \u2018invisible AI\u2019 threats like algorithmic drift, delivering operational compliance through Audit, Remediation, and Governance, without building internal teams.<\/p>\n<\/div>\n\n\n\n

\n<\/div>\n<\/div>\n\n\n\n
\n
\n

Reduce AI risks by an estimated 50%
with our 2-week Readiness Sprint, turning regulatory burdens into a competitive edge.<\/em><\/h3>\n<\/div>\n<\/blockquote>\n\n\n\n
\n\n\n\n
\n
\n
Request a Free Readiness Assessment<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

ACCESHIELD\u2122 (AccelShield) is a productized service line addressing urgent \u2018invisible AI\u2019 risks for emerging US biotechs in EU-inclusive trials. Leveraging Switzerland-based expertise and our EU AI Act Readiness Playbook, it provides turnkey defense through three phases: Audit (mapping vendors and gaps), Remediation (fixing issues like silent updates), and Governance (ongoing monitoring and controls). This execution-focused product ensures data defensibility under EU AI Act, GCP, GDPR, MDR\/IVDR, and bridges to FDA \u2018Context of Use\u2019 for global alignment\u2014avoiding delays, scrutiny, and credibility issues.<\/p>\n<\/div>\n\n\n\n

\n
\n
\n

Audit Phase:<\/strong> Maps AI vendor chains and identifies gaps for full visibility.<\/p>\n\n\n\n

Remediation Phase:<\/strong> Implements fixes like locking Tier A systems and building evidence packs.<\/p>\n\n\n\n

Governance Phase:<\/strong> Delivers continuous monitoring, aligned with NIS 2 for cybersecurity resilience.<\/p>\n<\/div>\n\n\n\n

\n
\n
Download Our EU AI Act Readiness Playbook<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n
\n

Step 1: Audit Phase<\/h3>\n\n\n\n

Conduct a thorough mapping of AI tools and vendor chains to identify gaps, using our 3-Tier Risk Framework for quick prioritization.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Step 2: Remediation Phase<\/h3>\n\n\n\n

Address high-risk issues with practical fixes, such as the 2-week Readiness Sprint to secure systems and create inspectable evidence packs.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Step 3: Governance Phase<\/h3>\n\n\n\n

Establish ongoing monitoring and change controls, ensuring resilience against drift and alignment with evolving regs like the Digital Omnibus Regulation.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

Benefits for Emerging Biotechs<\/h2>\n\n\n\n

Proactive Risk Mitigation:<\/strong> Slash AI threats by 50%, preventing mid-study delays and inspection issues.<\/p>\n\n\n\n

Effortless Multi-Region Compliance:<\/strong> Bridge EU AI Act\/GDPR to FDA standards without internal expertise.<\/p>\n\n\n\n

Operational Edge:<\/strong> Turn burdens into advantages with tools like \u2018once-only\u2019 reporting readiness.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>
\n

<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Frequently Asked Questions<\/h2>\n\n\n\n
\n
\n
\n